Journal of Thrombosis and Thrombolysis

, Volume 31, Issue 1, pp 85–91

Risk factors for ischemic stroke and transient ischemic attack in patients under age 50

  • A. W. M. Janssen
  • F. E. de Leeuw
  • M. C. H. Janssen
Open Access


To analyze risk factors for ischemic stroke and transient ischemic attack (TIA) in young adults under the age of 50. To make recommendations for additional research and practical consequences. From 97 patients with ischemic stroke or TIA under the age of 50, classical cardiovascular risk factors, coagulation disorders, history of migraine, use of oral contraceptives, cardiac abnormalities on ECG and echocardiography, and the results of duplex ultrasound were retrospectively analyzed. Literature was reviewed and compared to the results. 56.4% of the patients had hypertension, 12.1% increased total cholesterol, 20% hypertriglyceridemia, 31.5% an increased LDL-level, 32.6% a decreased HDL-level and 7.2% a disturbed glucose tolerance. Thrombophilia investigation was abnormal in 21 patients and auto-immune serology was abnormal in 15 patients. Ten of these patients were already known with a systemic disease associated with an increased risk for ischemic stroke (i.e. systemic lupus erythematosus). The ECG was abnormal in 16.7% of the cases, the echocardiography in 12.1% and duplex ultrasound of the carotid arteries was in 31.8% of the cases abnormal. Conventional cardiovascular risk factors are not only important in patients over the age of 50 with ischemic stroke or TIA, but also in this younger population under the age of 50. Thrombophilia investigation and/ or autoimmune serology should be restricted to patients without conventional cardiovascular risk factors and a history or other clinical symptoms associated with hypercoagulability and/ or autoimmune diseases.


Young stroke Thrombophilia Cardiovascular risk factors Echocardiography Duplex ultrasound 


Stroke is the most important cause of disablement in the western world. In the Netherlands it is the third cause of lost Disability-Adjusted Life-Years (DALY’s)––after coronary disease and anxiety diseases [1]. About 10% of all strokes occur in patients <50 years of age. Risk factors in these young stroke patients differ from those found in older people [2]. Etiology of ischemic stroke in young adults remains uncertain [3, 4] and multiple factors have been reported as risk factors like traditional vascular risk factors [5, 6], thrombophilia [6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], migraine [6, 19, 20, 21, 22], auto-immune disorders [23, 24, 25, 26, 27] and cardiac anomalies [6, 28, 29, 30, 31, 32, 33, 34, 35].

The present study aimed to determine classical risk factors and prevalence of thrombophilic risk factors and autoimmune serology in patients under the age of 50 with transient ischemic attack (TIA) or ischemic stroke. Furthermore the practical consequences of these investigations are discussed.

Patients and methods


This retrospective study included a series of 97 patients under the age of 50, diagnosed with ischemic stroke or TIA (after history taking, physical examination and brain imaging studies), admitted to the neurology department of the Radboud University Nijmegen Medical Centre between September 2004 and January 2008. Medical records of these patients were reviewed. The data of these patients were retrospectively analyzed and compared with literature.

Risk factors

The following data were collected: gender, age, type of event, smoking, use of oral contraceptives, cardiovascular history (previous stroke or TIA, myocardial infarction, venous thromboembolism, hypertension, hypercholesterolemia or pre-eclampsia/HELLP-syndrome/spontaneous abortion), positive family history for cardiovascular disease (first-degree female family members <65 years and first-degree male family members <55 years), migraine, diabetes, blood pressure (hypertension was classified as a blood pressure >140/90 mmHg or treatment with antihypertensive medication) ECG, echocardiography and duplex ultrasound of the extra cranial arteries.

Cardiac imaging

ECGs were analyzed. Almost all patients underwent two-dimensional transthoracic echocardiography (TTE). Potential cardiac sources of embolism were: patent foramen ovale (PFO), atrial septal aneurysm (ASA), mitral stenosis, mitral insufficiency, atrial fibrillation, endured myocardial infarction, endocarditis, intracardial thrombus, atrial myxoma, prosthetic valve, non-ischemic dilating cardiomyopathy and left ventricular akinesis.

Carotid ultrasound

The results of duplex ultrasound of the extra cranial arteries were divided in four categories: normal, non-significant atherosclerotic changes (e.g. slightly increased intima media thickness without significant haemodynamic changes), significant atherosclerotic changes (i.e. vascular stenosis with luminal reduction ≥50%) and other significant vascular damage (i.e. dissection).

Laboratory assays

The following laboratory data were evaluated: total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, glucose, protein C, free protein S and antithrombin activity, factor V Leiden, factor II mutation (prothrombin G202010A mutation), homocysteine, lupus anticoagulant and anticardiolipin antibodies (IgG and IgM), antinuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA).

Reference values were 70–150% for protein C, 65–130% and 55–115% respectively for men and women for free protein S, >80% for antithrombin, <15 μmol/l for homocysteine, <6.5 mmol/l for total cholesterol, <2.00 mmol/l for triglycerides, >1.10 mmol/l for HDL and <3.50 mmol/l for LDL cholesterol. The normal values for fasting blood sugar and non-fasting blood sugar were <6.1 and <7.8 mmol/l.


Cardiovascular risk factors

Of the 97 patients, 49 had an ischemic stroke and 48 had a TIA. Mean age of the study population was 41.3 ± 7.7 years (range 17.04–49.97 years) and 57 (58.8%) were females. The presence of the classical atherosclerotic risk factors are presented in Table 1. The most common cardiovascular risk factor was hypertension (56.4%), followed by a positive cardiovascular medical history (47.9%), a positive family history (44.4%) and smoking (40.0%). 32.6% of the patients had a decreased HDL-level. LDL was elevated in 31.5%. 73.2% of the patients had two or more cardiovascular risk factors. Only 8.5% had no cardiovascular risk factor.
Table 1

Demographic data and risk factors


All (n = 97)



Nonmodifiable risk factors

 Age, y

41.3 ± 7.7 (17.04–49.97)a

43.0 ± 7.2 (17.04–49.97)a

40.1 ± 7.8 (19.25–49.89)a


40 (41.2)

57 (58.8)

 Ischemic stroke (N)

49 (50.5)

19 (38.8)

30 (61.2)

 TIA (N)

48 (49.5)

21 (43.8)

27 (56.2)


Number scored (%)

Positive result (%)

Cardiovascular family history

90 (92.8)

40 (44.4)

Well-documented and modifiable risk factors

 Cardiovascular history

94 (96.9)

45 (47.9)

 Cigarette smoking

95 (97.9)

38 (40)


94 (96.9)

53 (56.4)


91 (93.8)

11 (12.1)


90 (92.8)

18 (20.0)

 Increased LDL

89 (91.8)

28 (31.5)

 Decreased HDL

89 (91.8)

29 (32.6)

 Glucose >7.8

97 (100)

7 (7.2)

 Glucose >6.1

97 (100)

19 (19.6)

Cardiovascular risk factorsb


82 (84.5)

7 (8.5)


82 (84.5)

15 (18.3)


82 (84.5)

21 (25.6)


82 (84.5)

16 (19.5)


82 (84.5)

14 (17.1)


82 (84.5)

8 (9.8)



1 (1.2)

Less well-documented, potentially modifiable risk factors

 History of migraine

94 (96.9)

19 (20.2)

 Oral contraceptive use

96 (99.0)/56 (98.2)

24 (25.0)/24 (42.9)

Data are expressed as mean ± SD or n(%)

TIA transient ischemic attack; LDL low-density lipoprotein; HDL high-density lipoprotein


bSmoking, hypertension, high glucose level, high total cholesterol, high triglycerides, high LDL, low HDL, significant changes of duplex ultrasound, positive cardiovascular history

Cardiac imaging

ECGs showed hardly any abnormalities (Table 2). Disturbed repolarisation was the most common abnormality (7.7%). In our population five patients had a PFO (6.4%) and also five patients (6.4%) had mitral insufficiency (Table 2). One patient had a congenital anomaly consisting of a pulmonary artery aplasia and hypoplastic right ventricle.
Table 2

Etiology of ischemic stroke/TIA


Positive result (%)

Echocardiography (n = 78)


5 (6.4)


1 (1.3)

 Mitralis stenosis


 Mitralis insufficience

5 (6.4)

 Atrial fibrilation


 Endured myocardial infarction

2 (2.6)



 Intracardial thrombus


 Atrial myxoma


 Prosthetic valve

2 (2.6)

 Non-ischemic dilating cardiomyopathy

1 (1.3)

 Left ventricular akinesis

2 (2.6)

 Congenital cardiac anomaly

1 (1.3)

ECG (n = 91)

 Sinus rhythm

91 (100)

 Atrial fibrillation


 Endured myocardial infarction


 Disturbed repolarisation

7 (7.7)

 Left ventricle hypertrophy

1 (1.1)

 Left bundle-branch block

1 (1.1)

 Congenital cardiac anomaly

2 (2.2)


 Protein C <70 (n = 82)

2 (2.4)

 Free Protein S: ♂ <65; ♀ <55 (n = 82)

1 (1.2)

 Antithrombin <80 (n = 85)

1 (1.2)

 Factor V Leidena (n = 85)

6 (7.1)

 Factor II mutationa (n = 84)

3 (3.6)

 Homocysteine >15 (n = 81)

11 (13.6)


 Lupus anticoagulant (n = 85)

1 (1.2)

 Anticardiolipine IgG (n = 83)

2 (2.4)

 Anticardiolipine IgM (n = 83)

1 (1.2)

 ANA (n = 86)

7 (8.1)

 ANCA (n = 81)

6 (7.4)

PFO patent foramen ovale, ASA atrial septal aneurysm; a Heterozygote

Gynaecological history

14% (8) of the women had a history of one or two spontaneous abortions. Three of them had a history of pre-eclampsia. 42.9% of the women used oral contraceptives (Table 1).


In our study group, 20.2% of the patients had a history of migraine. The combination of migraine and the use of oral contraception occurred in 9.3%, the combination of migraine and PFO in 3.1%. Sixty percentage of the patients with PFO were familiar with migraine.

Carotid ultrasound

The results of the duplex ultrasound are shown in Table 2. 20% of the patients had non-significant and 11.8% had significant atherosclerotic changes or dissection.

Thrombophilic and autoimmune investigations

Not all patients had a complete trombophilia and auto-immune work-up (Table 2). Increased homocysteine was present in 13.6%. The two patients with mildly decreased protein C and the patient with decreased protein S used oral contraceptives. The auto-immune research resulted in a positive ANA in 8.1% and a positive ANCA in 7.4%. Studying the history of the patients, we found that a disorder associated with increased blood coagulation and/or vasculitis in combination with ischemic stroke was present in 17 patients (Table 3). This group represented 1/2 decreased protein C, 1/1 decreased antithrombin, 1/1 positive lupus anticoagulant, 3/6 FVL, 1/3 factor II mutation, 5/7 positive ANA and 2/6 positive ANCA (divided over 10 patients). Two patients in Table 2 were not screened for trombophilia and auto-immune disorders.
Table 3

Disorders associated with increased blood coagulation/vasculitis




Systemic lupus erythematosus


1 with positive ANA and lupus anticoagulant; one with positive ANA, FVL and factor II mutation

Colitis ulcerosa


1 with positive ANA; one with positive ANCA

M. Crohn


1 with FVL; one with decreased PC and AT

Systemic malignancy


1 with Non-Hodgkin lymphoma; one with Hodgkin lymphoma

Rheumatoid arthritis


Positive ANA

Syndrome of Sneddon


Positive ANCA

Moya Moya syndrome






Discoid lupus erythematosus



M. Buerger



Anti-Jo-1-antibodies syndrome


Positive ANA

Thrombotic thrombocytopenic purpura



Polycythaemia vera



Total n(% of total patient population)

17 (17.5%)


ANA anti-nuclear antibodies, FVL factor V Leiden, ANCA anti-neutrophil cytoplasmic antibodies, PC protein C, AT antithrombin

aTwo patients were not screened for thrombophilia and auto-immune disorders

Some patients showed more than one abnormality. One patient known with SLE had a positive ANA and lupus anticoagulant; one patient with SLE presented with positive ANA, FVL and factor II mutation; one patient known with M. Crohn had a decreased protein C and antithrombin; a patient with decreased protein C and FVL had a history of pre-eclampsia and two spontaneous abortions; one patient with a blank history showed a positive ANA and anticardiolipin IgG.

None of the patients with a coagulation disorder had a PFO.


The results of the present study demonstrate that conventional cardiovascular risk factors are not only an important risk factor in patients over the age of 50 with ischemic stroke/TIA, but also in this younger population under the age of 50.

Almost half of the patients (47.9%) had a positive cardiovascular history. Eight of these patients had a history of spontaneous abortions and/or pre-eclampsia. Also the family history for cardiovascular disease was frequently positive (44.4%). In the Netherlands, 28% of the general population was smoking at that time [36], in our population 40% was smoking. The results of the lipids and glucose values are difficult to compare with results from the literature because of different cut-off values.

58.8% of our population was of the female gender. This is comparable with the literature [37]. The higher proportion of women is possibly due to the nature of risk factors for stroke/TIA at younger age; like pregnancy, migraine en oral contraceptives use. These risk factors tend to occur more frequently in women.

We found a history of migraine in 20.2% of the population. This is analogous to the results of Milhaud et al. [19]. They found migraine in 29.3% of their population, which was younger (<35 years). Furthermore they found 18.2% of the patients with migraine (<45 years) having a PFO. This is analogous to our results (15.8%). Of all women in our study 42.9% used oral contraceptives. This is comparable to the Dutch population between 20 and 45 years old (41%) [38].

In contrast to what is known from literature, a small number of cardiac anomalies was detected by echocardiography. Kittner [3] and Rodes-Cabau et al. [33] described cardiogenic emboli as the most common cause of ischemic stroke in younger persons (15.4%). PFO and atrial septal aneuryms (ASA) are described in literature as the most common cardiac anomaly found in stroke/TIA [28, 29, 30, 31, 32]. Cabanes et al. [28] distinguished PFO in 43% and ASA in 28% of the population <55 years old. In our study PFO was detected in only 6.4% and ASA in 1.3% of the patients. This discrepancy can be explained by the difference in technique of echocardiography. Cabanes et al. [28] used––like most of the other investigators [29, 30, 31, 32]––transesophageal echocardiography (TEE), instead of TTE. It is suggested that the transesophageal technique is more sensitive in detecting interatrial septum anomalies (PFO, ASA, atrial septal defect), atrial thrombi during atrial fibrillation and mitral valve vegetations like endocarditis [35].

Most of the abnormalities found in thrombophilia- and auto-immune investigations, were detected in patients already known with diseases associated with an increased coagulation before the stroke occurred. Furthermore all patients with decreased protein C and S used oral contraception, which is a known cause of decreased protein C and S [18].

Hankey et al. [8] demonstrated no significant differences between patients with young stroke and controls for protein C, S and antithrombin levels. Amiri et al. [9] did not find decreased levels of protein C and antithrombin at all. The percentages of protein C and S that Hankey et al detected are in the range with the percentages we found, except for the antithrombin level. We found a decreased antithrombin level in only 1.2% of the patients compared to 5.2% of Amiri et al.

The percentage of our patients with FVL and factor II mutations (7.1 and 3.6%) is in accordance with the results of the literature [8, 10, 14, 15, 16]; none of these studies reported significant differences between patients and controls, or just a minimal increased risk. It has to be noted that positive trombophilia screening has no practical consequences for the patient. There is no difference in kind and duration of anticoagulant treatment between patients with or without a thrombophilic factor.

The homocysteine level was increased in 11 patients. Nowadays it is questionable whether it is still useful to investigate homocysteine levels, since large placebo-controlled trials are published concerning the effect of treating hyperhomocysteinemia [39, 40, 41, 42]. Patients (with hyperhomocysteinemia) in these studies had a positive vascular history or a myocardial infarction. Vitamin supplementation caused no significant decrease of recurrence hazard of cardiovascular events. Only Saposnik et al. [43] concluded that vitamin supplementation reduces the risk of overall stroke (ischemic and haemorrhagic), but not stroke severity or disability in a population with and without history of cerebrovascular disease.

In our population a few patients with positive antiphospholipid antibodies were found (1.2%). Brey et al. [24] found a prevalence of 26.9% of antiphospholipid antibodies and a prevalence of 14% of anticardiolipin IgG and 0.6% of anticardiolipin IgM. Difference with our population is the fact they only measured all antibodies once, without the corroboration of a second measurement. The patients in our population had a positive test result repeatedly. Munts et al. [2] found a confirmed prevalence of anticardiolipin IgG of 17%. Nencini et al. [25] found prevalences of 18, 9 and 7% for antiphospholipid antibodies, anticardiolipin IgG and IgM.

Urbanus et al. [26] found lupus anticoagulant to be a significant risk factor (OR 43.1) for arterial thrombotic event in women under age 50. Antiphospholipid antibodies were present in 17% of the patients. The APASS investigators [27] concluded that the presence of antiphospholipid antibodies does not predict an increased risk for subsequent vascular occlusive events in patients with a non-cardiogenic stroke. And thereby may not offer enough value for decisions on therapy.

In contrast to the literature [29, 30] we did not identify a combination of thrombophilia and PFO in our population. This can be caused by a low prevalence of both parameters in our population. Furthermore the size of our population is too small to demonstrate an association. Belvís [31] and Florez et al. [34] did not find a significant association between patients with and without PFO for coagulation disorders.

A limitation of this study is that it is retrospective, resulting in incomplete data. Strength of the study is that we investigated many possible risk factors for ischemic stroke in one study. Many studies investigated just one or few risk factors in relation to ischemic stroke. Additional prospective, controlled studies of ischemic stroke/TIA patients under age 50 are needed to better assess the roles of the risk factors in the etiology of ischemic stroke/TIA. A relation between migraine and stroke should be corroborated by further studies.

Conclusion and recommendations

Screening for conventional cardiovascular risk factors remains the most important considering the high percentage of cardiovascular risk factors in patients under age 50. These high frequencies also indicate optimal secondary prevention strategies.

Based on the low laboratory yield of thrombophilia- and auto-immune search, it is not indicated to do this complete laboratory search in all patients under 50, especially not when there is no history related to these diseases. Furthermore in most cases a positive thrombophilic factor has no therapeutic consequences, such as switching of type of anticoagulation or duration of anticoagulation. Thrombophilia and auto-immune research is only indicated in specific cases.

Because of the low number of abnormalities found in TTE, TEE seems preferable instead. Disadvantage of the transesophageal technique is its more invasive nature. Another possibility is the use of TEE in selected young patients, without other risk factors for ischemic stroke.

The ECG should be used to exclude atrial fibrillation. It is cheap and simple.

The use of duplex ultrasound of the extra cranial arteries should be continued. It is a non-invasive test and gives information about the presence of atherosclerosis or dissection in the carotid arteries. Is has a sensitivity of 86% and specificity of 87% [44].

History taking remains important in detecting risk factors. Characteristics of auto-immune diseases could be specifically interrogated.

The recommendation for diagnostic testing for possible etiologies and risk factors of ischemic stroke or transient ischemic attack in patients under age 50 is summarized in Fig. 1. The suggested scheme developed on the basis of the results of this study should be further validated in prospective studies.
Fig. 1

Recommendation for diagnostic testing in patients with young stroke


Sources of Funding

Dr De Leeuw received a personal fellowship of the Dutch Brain foundation (H04-12) and a clinical fellowship of the Netherlands Organization for Scientific Research (Project Number: 40-00703-97-07197).

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.


  1. 1.
    Poos MJJC, van der Wilk EA. Sterfte naar doodsoorzaak samengevat. Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Gezondheid en ziekte\ Sterfte, levensverwachting en DALY’s\ Sterfte naar doodsoorzaa. December 2008
  2. 2.
    Munts AG, van Genderen PJ, Dippel DW, van Kooten F, Koudstaal PJ (1998) Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 245:21–25CrossRefPubMedGoogle Scholar
  3. 3.
    Kittner SJ, Stern BJ, Wozniak M, Buchholz DW, Earley CJ, Feeser BR, Johnson CJ, Macko RF, McCarter RJ, Price TR, Sherwin R, Sloan MA, Wityk RJ (1998) Cerebral infarction in young adults, the Baltimore-Washington cooperative young stroke study. Neurology 50:890–894PubMedGoogle Scholar
  4. 4.
    Leys D, Bandu L, Henon H, Lucas C, Mounier-Vehier F, Rondepierre P, Godefroy O (2002) Clinical outcome in 287 consecutive young adults (15 tot 45 years) with ischemic stroke. Neurology 59:26–33PubMedGoogle Scholar
  5. 5.
    Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL (2006) Primary prevention of ischemic stroke. Stroke 37:1583–1633PubMedGoogle Scholar
  6. 6.
    Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, Kaste M, Taklisumak T (2009) Analysis of 1008 consecutive patients aged 15 to 49 with firts-ever ischemic stroke. The Helsinki young stroke registry. Stroke 40:1195–1203CrossRefPubMedGoogle Scholar
  7. 7.
    Rahemtullah A, van Cott EM (2007) Hypercoagulation testing in ischemic stroke. Arch Pathol Lab Med 131:890–901PubMedGoogle Scholar
  8. 8.
    Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI (2001) Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 32:1793–1799Google Scholar
  9. 9.
    Amiri M, Schmidley JW, Fink LM, Nazarian SM (2000) Is testing for inherited coagulation inhibitor deficiencies in young stroke patients worth wile? Clin Neurol Neurosurg 102:219–222CrossRefPubMedGoogle Scholar
  10. 10.
    Aznar J, Mira Y, Vayá A, Corella D, Ferrando F, Villa P, Estellés A (2004) Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost 91:1031–1034PubMedGoogle Scholar
  11. 11.
    Wu AHB, Tsongalis GJ (2001) Correlation of polymorphisms to coagulation, bichemical risk factors for cardiovascular diseases. Am J Cardiol 87:1361–1366CrossRefPubMedGoogle Scholar
  12. 12.
    Kim RJ, Becker RC (2003) Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofoloate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 146:948–957Google Scholar
  13. 13.
    Casas JP, Hingorani AD, Bautista LE, Sharma P (2004) Meta-analysis of genetic studies in ischemic stroke. Arch Neurol 61:1652–1662CrossRefPubMedGoogle Scholar
  14. 14.
    Madonna P, de Stefano V, Coppola A, Cirillo F, Cerbone AM, Orefice G, Di Minno G (2002) Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 33:51–56CrossRefPubMedGoogle Scholar
  15. 15.
    Longstreth WT Jr, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, Raghunathan TE, Koepsell TD, Reitsma PH (1998) Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 29:577–580PubMedGoogle Scholar
  16. 16.
    Zunker P, Hohenstein C, Plendl HJ, Zeller JA, Caso V, Georgiadis D, Allardt A, Deuschl G (2001) Activated protein C resistance and acute ischemic stroke: relation to stroke causation and age. J Neurol 248:701–704CrossRefPubMedGoogle Scholar
  17. 17.
    Møller J, Nielsen GM, Tvedegaard KC, Andersen NT, Jørgensen PE (2000) A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest 60:491–500CrossRefPubMedGoogle Scholar
  18. 18.
    Bushnell CD, Goldstein LB (2000) Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 31:3067–3078PubMedGoogle Scholar
  19. 19.
    Milhaud D, Bogousslavsky J, van Melle G, Liot P (2001) Ischemic stroke, active migraine. Neurology 57:1805–1811PubMedGoogle Scholar
  20. 20.
    Moschiano F, D’Amico D, Ciusani E, Erba N, Rigamonti A, Schieroni F, Bussone G (2004) Coagulation abnormalities in migraine and ischaemic cerebrovascular disease: a link between migraine and ischemic stroke? Neurol Sci 25:S126–S128CrossRefPubMedGoogle Scholar
  21. 21.
    Etminan M, Takkouche B, Caamaño Isorna F, Samii A (2005) Risk of ischaemic stroke in people with migraine: systemic review and meta-analysis of observational studies. BMJ 330:63CrossRefPubMedGoogle Scholar
  22. 22.
    Chang CL, Donahy M, Poulter N (1999) Migraine, stroke in young women: case-control study. BMJ 318:13–18PubMedGoogle Scholar
  23. 23.
    Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK (2000) Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke 31:1289–1293PubMedGoogle Scholar
  24. 24.
    Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Sherwin R, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz DW, Hebel JR, Kittner SJ (2002) Antiphospholipid antibodies and stroke in young women. Stroke 33:2396–2401CrossRefPubMedGoogle Scholar
  25. 25.
    Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D (1992) Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 23:189–193PubMedGoogle Scholar
  26. 26.
    Urbanus RT, Siegerink B, Roest M, Rosendaal MR, de Groot PG, Algra A (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 8:998–1005CrossRefPubMedGoogle Scholar
  27. 27.
    Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. Committee, The APASS Writing (2004) JAMA 291:576–584Google Scholar
  28. 28.
    Cabanes L, Mas JL, Cohen A, Amarenco P, Cabanes PA, Oubary P, Chendru F, Guerin F, Bousser MG, de Recondo J (1993) Atrial septum aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 24:1865–1873PubMedGoogle Scholar
  29. 29.
    Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG (2007) Prothrombotic mutations as risk factor for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 38:2070–2073CrossRefPubMedGoogle Scholar
  30. 30.
    Karttunen V, Hiltunen L, Rasi V, Vahtera E, Hillbom M (2003) Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis 14:261–268CrossRefPubMedGoogle Scholar
  31. 31.
    Belvís R, Santamaría A, Martí-Fàbregas J, Leta RG, Cocho D, Borrell M, Fontcuberta J, Martí-Vilalta JL (2007) Patent foramen ovale and prothrombotic markers in young stroke patients. Blood Coagul Fibrinolysis 18:537–542CrossRefPubMedGoogle Scholar
  32. 32.
    Offelli P, Zanchetta M, Pedon L, Marzot F, Cucchini U, Pegoraro C, Iliceto S, Pengo V (2007) Thrombophilia in young patients with cryptogenic stroke and patent foramen ovale (PFO). Thromb Haemost 98:906–907PubMedGoogle Scholar
  33. 33.
    Rodés-Cabau J, Noël M, Marrero A, Rivest D, Mackey A, Houde C, Bédard E, Larose E, Verreault S, Peticlerc M, Pibarot P, Bogaty P, Bertrand OF (2009) Athersclerotic burden findings in young cryptogenic stroke patients with and without a patent foramen ovale. Stroke 40:419–425CrossRefPubMedGoogle Scholar
  34. 34.
    Florez JC, Ay H, van Cott EM, Buonanno FS (2003) Patent foramen ovale and hypercoagulability as combined risk factors for stroke. J Stroke Cerebrovasc Dis 339:589–594Google Scholar
  35. 35.
    Hart RG (1992) Cardiogenic embolism to the brain. Lancet 339:589–594CrossRefPubMedGoogle Scholar
  36. 36.
  37. 37.
    Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE (1998) Stroke incidence among white. black, and hispanic residents of an urban community. Am J Epidemiol 147:259–268PubMedGoogle Scholar
  38. 38.
  39. 39.
    Lonn E (2007) Homocysteine in the prevention of ischemic heart disease, stroke, venous thromboembolism: therapeutic target or just another distraction? Curr Opin Hematol 14:481–487PubMedGoogle Scholar
  40. 40.
    Lonn E, Yusuf S, Phil D, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567–1577CrossRefPubMedGoogle Scholar
  41. 41.
    Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen J, Rasmussen K (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354:1578–1588CrossRefPubMedGoogle Scholar
  42. 42.
    Bazzano LA, Reynolds K, Holder KN, He J (2006) Folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trial. JAMA 296:2720–2726CrossRefPubMedGoogle Scholar
  43. 43.
    Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E (2009) Homocysteine-lowering therapy and stroke risk. Severity, and disability; additional findings from the HOPE 2 trial. Stroke 40:1365–1372CrossRefPubMedGoogle Scholar
  44. 44.
    Nederkroon PJ, van der Graaf Y, Hunink MG (2003) Duplex ultrasound and magnetic resonance angiography compared with digital subtraction angiography in carotid artery stenosis: a systemic review. Stroke 34:1324–1332CrossRefGoogle Scholar

Copyright information

© The Author(s) 2010

Authors and Affiliations

  • A. W. M. Janssen
    • 1
  • F. E. de Leeuw
    • 2
  • M. C. H. Janssen
    • 1
  1. 1.Department of Internal MedicineRadboud University Nijmegen Medical CentreNijmegenThe Netherlands
  2. 2.Donders Institute for Brain, Cognition and Behaviour, Centre for Neuroscience, Department of NeurologyRadboud University Nijmegen Medical CentreNijmegenThe Netherlands

Personalised recommendations